These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29530037)

  • 1. Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer.
    Zambrano-Estrada X; Landaverde-Quiroz B; Dueñas-Bocanegra AA; De Paz-Campos MA; Hernández-Alberto G; Solorio-Perusquia B; Trejo-Mandujano M; Pérez-Guerrero L; Delgado-González E; Anguiano B; Aceves C
    BMC Vet Res; 2018 Mar; 14(1):87. PubMed ID: 29530037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection.
    Alfaro Y; Delgado G; Cárabez A; Anguiano B; Aceves C
    Mol Cancer; 2013 May; 12():45. PubMed ID: 23705792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin.
    Bontempo A; Ugalde-Villanueva B; Delgado-González E; Rodríguez ÁL; Aceves C
    Oncol Rep; 2017 Nov; 38(5):2867-2876. PubMed ID: 28901484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular iodine exerts antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts.
    Mendieta I; Nuñez-Anita RE; Nava-Villalba M; Zambrano-Estrada X; Delgado-González E; Anguiano B; Aceves C
    BMC Cancer; 2019 Mar; 19(1):261. PubMed ID: 30902074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study.
    Moreno-Vega A; Vega-Riveroll L; Ayala T; Peralta G; Torres-Martel JM; Rojas J; Mondragón P; Domínguez A; De Obaldía R; Avecilla-Guerrero C; Anguiano B; Delgado-González E; Zambrano-Estrada X; Cuenca-Micó O; De La Puente Flores O; Varela-Echavarría A; Aceves C
    Nutrients; 2019 Jul; 11(7):. PubMed ID: 31319484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of efficacy of two different chemotherapy protocols used in neoadjuvant chemotherapy in clinical stages II-IV canine malignant mammary tumours.
    Kuruoglu FE; Ekici ZM; Nak D; Ozyigit MO; Kupeli ZA; Koca D
    Vet Comp Oncol; 2024 Jun; 22(2):284-294. PubMed ID: 38600051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel.
    Simon D; Schoenrock D; Baumgärtner W; Nolte I
    J Vet Intern Med; 2006; 20(5):1184-90. PubMed ID: 17063714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
    Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
    BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.
    Bakirel T; Alkan FÜ; Üstüner O; Çinar S; Yildirim F; Erten G; Bakirel U
    J Vet Med Sci; 2016 May; 78(4):657-68. PubMed ID: 26822118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer.
    Sobral RA; Honda ST; Katayama ML; Brentani H; Brentani MM; Patrão DF; Folgueira MA
    Acta Vet Scand; 2008 Jul; 50(1):27. PubMed ID: 18601734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma.
    Guil-Luna S; Stenvang J; Brünner N; De Andrés FJ; Rollón E; Domingo V; Sánchez-Céspedes R; Millán Y; Martín de Las Mulas J
    BMC Vet Res; 2014 Dec; 10():296. PubMed ID: 25515784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
    Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
    J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting canine mammary tumours via gold nanoparticles functionalized with promising Co(II) and Zn(II) compounds.
    Raposo LR; Roma-Rodrigues C; Jesus J; Martins LMDRS; Pombeiro AJ; Baptista PV; Fernandes AR
    Vet Comp Oncol; 2017 Dec; 15(4):1537-1542. PubMed ID: 28150469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and pharmacokinetic profile of a novel benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride in dogs with malignant mammary tumours.
    Kristiansen VM; Dewi S; Horsberg TE; Jonasdottir TJ; Moe L; Berlinger B; Lindkaer-Jensen S; Larsen S
    Vet Comp Oncol; 2017 Mar; 15(1):118-132. PubMed ID: 25764447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of neoadjuvant aglepristone treatment in clinicopathological parameters of progesterone receptor-positive canine mammary carcinomas.
    Guil-Luna S; Millán Y; De Andres J; Rollón E; Domingo V; García-Macías J; Sánchez-Céspedes R; Martín de Las Mulas J
    Vet Comp Oncol; 2017 Jun; 15(2):391-399. PubMed ID: 26781329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) treatment Evidence that I2 prevents cancer promotion.
    García-Solís P; Alfaro Y; Anguiano B; Delgado G; Guzman RC; Nandi S; Díaz-Muñoz M; Vázquez-Martínez O; Aceves C
    Mol Cell Endocrinol; 2005 May; 236(1-2):49-57. PubMed ID: 15922087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of doxorubicin-based chemotherapy for non-resectable canine subcutaneous haemangiosarcoma.
    Wiley JL; Rook KA; Clifford CA; Gregor TP; Sorenmo KU
    Vet Comp Oncol; 2010 Sep; 8(3):221-33. PubMed ID: 20691029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aglepristone decreases proliferation in progesterone receptor-positive canine mammary carcinomas.
    Guil-Luna S; Sánchez-Céspedes R; Millán Y; De Andrés FJ; Rollón E; Domingo V; Guscetti F; Martín de Las Mulas J
    J Vet Intern Med; 2011; 25(3):518-23. PubMed ID: 21488964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma.
    McNeill CJ; Sorenmo KU; Shofer FS; Gibeon L; Durham AC; Barber LG; Baez JL; Overley B
    J Vet Intern Med; 2009; 23(1):123-9. PubMed ID: 19175730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-iodolactone, key mediator of antitumoral properties of iodine.
    Nava-Villalba M; Aceves C
    Prostaglandins Other Lipid Mediat; 2014 Aug; 112():27-33. PubMed ID: 25018052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.